Komori
Occurring Fact4583Chiome Bioscience Inc.Pharmaceuticals

Notice Regarding the Recording of Non-Operating Expenses

The ¥4.144 million registration and license tax associated with the amended registration for the issuance of new shares upon exercise of the 23rd Series of Stock Acquisition Rights was recorded as share issuance costs (non-operating expense) for the nine-month period ended 30 September 2026 and reflected in the earnings summary for the same period.

Worth reading
33Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
4144
¥ thousand
Wording
Definitive
How definitive the wording is.

Recognition of share issuance costs (non-operating expense)

Subject Entity

Chiome Bioscience Inc.

Target Locations / Products

Amended registration associated with the issuance of new shares upon exercise of the 23rd Series of Stock Acquisition Rights

This disclosure11/10/2026
Cause

Registration and license tax associated with the amended registration for the issuance of new shares upon exercise of the 23rd Series of Stock Acquisition Rights

Amount of Impact on Business Performance

¥4.144 million (share issuance costs, non-operating expense)

Accounting period in which recognized

Nine-month period ended 30 September 2026 (1 January 2026 to 30 September 2026)

Event that occurred
ItemDetails
Event nameRecognition of share issuance costs (non-operating expense)
Subject EntityChiome Bioscience Inc.
Target Locations / ProductsAmended registration associated with the issuance of new shares upon exercise of the 23rd Series of Stock Acquisition Rights
CauseRegistration and license tax associated with the amended registration for the issuance of new shares upon exercise of the 23rd Series of Stock Acquisition Rights
Amount of Impact on Business Performance¥4.144 million (share issuance costs, non-operating expense)
Accounting period in which recognizedNine-month period ended 30 September 2026 (1 January 2026 to 30 September 2026)
Items this document does not state (19)
Date of occurrenceDate recognized / date notice receivedImpact on Earnings ForecastType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changeOutlookPlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because it is registration and license tax associated with the amended registration for the issuance of new shares upon exercise of the 23rd Series of Stock Acquisition Rights.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Recording of Non-Operating Expenses | Chiome Bioscience Inc. (4583) timely disclosure | Komori